微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-09-30 | 34.09% | 16.27% | 2.38% | 105/159 | 50.44% | 迪哲医药 | 99.22% | 行业排名> |
| 2026-06-30 | 33.3% | 14.87% | 0.64% | 105/159 | 48.66% | 海创药业 | 97.34% | 行业排名> |
| 2026-03-31 | 33.09% | 13.06% | 11.23% | 105/159 | 50.28% | 海创药业 | 99.82% | 行业排名> |
| 2025-12-31 | 29.75% | 16.57% | 1.46% | 118/159 | 50.37% | 海创药业 | 98.62% | 行业排名> |
| 2025-09-30 | 29.32% | 14.42% | 1.15% | 118/159 | -2.13% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 28.98% | 13.62% | -0.95% | 120/159 | 15.05% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 29.26% | 18.18% | 14.68% | 114/159 | 31.79% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 25.52% | -13.07% | -0.41% | 128/159 | 51.61% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 25.62% | -13.13% | 0.44% | 127/159 | 22.43% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 25.51% | -14.83% | 3.02% | 127/159 | 32.96% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 24.76% | -13.9% | -15.65% | 127/159 | 51.47% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 29.36% | 7.46% | -0.47% | 122/159 | 51.31% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 29.5% | 4.05% | -1.52% | 120/159 | 32.31% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 29.95% | 7.93% | 4.15% | 120/159 | 38.22% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 28.76% | 7.41% | 5.27% | 119/159 | 52.66% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 27.32% | -14.63% | -3.63% | 125/159 | 53.51% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 28.35% | -11.38% | 2.14% | 118/159 | 5.67% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 27.75% | -6.8% | 3.65% | 125/159 | 20.91% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 26.77% | -0.28% | -16.33% | 120/159 | 54.06% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 32% | 0.47% | 0.04% | 121/159 | 54.9% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 31.99% | -13.97% | 7.43% | 104/159 | 46.49% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 29.78% | -17.12% | 10.91% | 123/159 | 46.97% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 26.85% | -27.02% | -15.71% | 109/159 | 53.79% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 31.85% | -12% | -14.33% | 123/159 | -147.51% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 37.18% | 2.84% | 3.5% | 95/159 | 56.06% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 35.93% | 1.87% | -2.34% | 104/159 | 53.85% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 36.79% | 9.18% | 1.63% | 85/159 | 54.83% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 36.19% | 8.75% | 0.11% | 106/159 | -1232.76% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 36.15% | 9.53% | 2.52% | 85/159 | 54.86% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 35.27% | 3.29% | 4.67% | 90/159 | 54.88% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 33.69% | -0.75% | 1.24% | 86/159 | 50.75% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 33.28% | -7.55% | 0.82% | 105/159 | -210.26% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 33.01% | -10.67% | -3.32% | 83/159 | 53.75% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 34.14% | -10.11% | 0.58% | 83/159 | 53.16% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 33.95% | -10.85% | -5.71% | 78/159 | 53.78% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 36% | -15.6% | -2.58% | 87/159 | 52.25% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 36.95% | -14.58% | -2.71% | 66/159 | 48.76% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 37.98% | -15.68% | -0.25% | 68/159 | 47.61% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 38.08% | 2% | -10.74% | 54/159 | 46.62% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 42.66% | -4.07% | -1.39% | 62/159 | 48.17% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 43.26% | 2% | -3.97% | 39/159 | 45.83% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 45.05% | 2% | 1.3% | 42/159 | 45.93% | 微芯生物 | 97.46% | 行业排名> |